Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trialWinfried Randerath, Samuel Genzor, J. Bravo Albares et al.|The Lancet|2025Cited by 15
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Marzena Fabis-Pedrini, Sifat Sharmin et al.|Journal of Neurology Neurosurgery & Psychiatry|2026Cited by 0